BioCryst Pharmaceuticals Inc BCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
-
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
-
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
-
BioCryst Appoints Dr. Donald Fong Chief Medical Officer
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
BioCryst to Present at Upcoming Investor Conferences
-
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
Trading Information
- Previous Close Price
- $7.42
- Day Range
- $7.44–7.63
- 52-Week Range
- $4.03–8.88
- Bid/Ask
- $7.40 / $7.57
- Market Cap
- $1.57 Bil
- Volume/Avg
- 1.0 Mil / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.98
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 531
- Website
- https://www.biocryst.com
Comparables
Valuation
|
Metric
|
BCRX
|
02509
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 16.86 |
Price/Book Value | — | 32.68 | 6.39 |
Price/Sales | 3.98 | 100.25 | 4.48 |
Price/Cash Flow | — | — | 14.92 |
Price/Earnings
BCRX
02509
MRK
Financial Strength
|
Metric
|
BCRX
|
02509
|
MRK
|
|---|---|---|---|
Quick Ratio | 2.64 | 1.70 | 0.88 |
Current Ratio | 2.82 | 1.86 | 1.47 |
Interest Coverage | −0.61 | −18.42 | 13.07 |
Quick Ratio
BCRX
02509
MRK
Profitability
|
Metric
|
BCRX
|
02509
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | −27.75% | −47.40% | 15.46% |
Return on Equity (Normalized) | — | −341.08% | 41.15% |
Return on Invested Capital (Normalized) | −14.10% | −56.34% | 22.92% |
Return on Assets
BCRX
02509
MRK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hnlqrqqrr | Scsqx | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jfnhrhll | Rlfvz | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Htztphyf | Pdvzc | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jvbqrpdxr | Dqkrdv | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Ggmslxcy | Rcps | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Fpplcnkw | Bgh | $29.2 Bil | |||
| Moderna Inc
MRNA
| Khkcssrk | Wbj | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Tdgsbffb | Gbzz | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xnqxyhgx | Hbjbngv | $13.2 Bil | |||
| Incyte Corp
INCY
| Fdrshvt | Ddhhs | $13.0 Bil |
United States